Objective: To analyze the expression of MCP-1 and CCR2 in newly diagnosed diffuse large B-cell lymphoma (DLBCL), and to evaluate their correlation with clinicopathological features and prognosis.
Methods: A total of 141 patients with DLBCL diagnosed and treated in the Department of Hematology, the First Affiliated Hospital of Bengbu Medical College from January 2017 to May 2022 were retrospectively collected. The clinical characteristics, pathological data and prognostic factors of the patients were collected. Immunohistochemical staining was used to detect the expression of MCP-1 and CCR2 in the tissues of newly treated DLBCL patients, and to analyze the relationship between MCP-1 and clinical characteristics, prognosis and survival of patients.
Results: The expression of MCP-1 and CCR2 were correlated with Ann Arbor stage, IPI score, lactate dehydrogenase (LDH), Ki-67 index and therapeutic effect. There were no significant correlation between the expression of MCP-1 or CCR2 and other clinical histopathological parameters such as gender, age, β2-microglobulin, BCL-2, BCL-6, Hans classification, initial location, B symptoms, bone marrow involvement. There was a statistical difference in OS and PFS between the MCP-1 or CCR2 positive group and the negative group, which was associated to poor prognosis.Univariate Cox regression analysis showed that β2-microglobulin, Ki-67 index, IPI score, MCP-1, CCR2 expression levels and disease remission affected the PFS and OS of DLBCL patients (P < 0.05). Gender, age, LDH, BCL-2, BCL-6, Hans classification, primary tumor site, B symptoms, bone marrow involvement, Ann Arbor stage had no effect on PFS and OS (P >0.05). Multivariate analysis showed that β2-microglobulin, Ki-67 index, IPI score, MCP-1, CCR2 expression levels and disease remission were independent influencing factors of patients (P < 0.05).
Conclusion: The expression rate of MCP-1 or CCR2 in newly treated DLBCL is high, and it is correlated with the clinical features of poor prognosis such as stage and LDH of DLBCL patients, which is a poor prognostic factor affecting PFS and OS.
题目: MCP-1及CCR2在初诊弥漫大B细胞淋巴瘤中的表达及临床意义.
目的: 分析MCP-1及CCR2在初治弥漫大B细胞淋巴瘤（DLBCL）组织中的表达，并评估其与临床病理特征和预后的相关性。.
方法: 回顾性收集2017年1月至2022年5月期间蚌埠医学院第一附属医院血液科确诊及治疗的141例初治DLBCL患者的临床特征、病理学资料，通过免疫组化染色检测MCP-1及CCR2在初治DLBCL患者组织中的表达情况，分析其与患者的临床特征、预后及生存的关系。.
结果: MCP-1及CCR2的表达与DLBCL患者Ann Arbor分期晚、IPI评分高、乳酸脱氢酶（LDH）升高、Ki-67指数高及疗效差有关，与其他病理学参数（如性别、年龄、β2-微球蛋白、BCL-2、BCL-6、Hans分型、首发部位、有无B症状、骨髓是否受累）均无显著相关性。生存曲线分析显示，MCP-1或CCR2阳性组与阴性组OS及PFS具有统计学差异，且与预后不良有关。单因素Cox回归法分析结果显示，β2-微球蛋白、Ki-67指数、IPI评分、MCP-1、CCR2表达水平对患者的PFS和OS有影响，疗效不佳的患者的PFS和OS明显缩短(P <0.05)，性别、年龄、LDH、BCL-2、BCL-6、Hans分型、肿瘤原发部位、有无B症状、骨髓是否受累、Ann Arbor分期对患者的PFS及OS无影响（P >0.05）。多因素分析结果表明，β2-微球蛋白高表达、Ki-67指数高、IPI评分高、MCP-1、CCR2高表达水平及疾病缓解的深度是患者预后不良的独立影响因素(P < 0.05)。.
结论: MCP-1或CCR2在初治DLBCL中表达率高，且与DLBCL患者Ann Arbor分期、IPI评分、LDH及Ki-67指数相关预后差的临床指标有关，是影响PFS和OS的不良预后因素。.
Keywords: immunohistochemical; CCR2; MCP-1; diffuse large B cell lymphoma.